AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans
B Georgievska, J Sandin, J Doherty… - Journal of …, 2013 - Wiley Online Library
Abnormal tau phosphorylation resulting in detachment of tau from microtubules and
aggregation are critical events in neuronal dysfunction, degeneration, and neurofibrillary …
aggregation are critical events in neuronal dysfunction, degeneration, and neurofibrillary …
Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease
HC Huang, PS Klein - Current drug targets, 2006 - ingentaconnect.com
Alzheimer's disease (AD) is a common neurodegenerative disorder that presents clinically
as inexorable cognitive impairment and decline in performance of activities of daily living …
as inexorable cognitive impairment and decline in performance of activities of daily living …
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
L Serenó, M Coma, M Rodriguez… - Neurobiology of …, 2009 - Elsevier
Amyloid deposits, neurofibrillary tangles, and neuronal cell death in selectively vulnerable
brain regions are the chief hallmarks in Alzheimer's (AD) brains. Glycogen synthase kinase …
brain regions are the chief hallmarks in Alzheimer's (AD) brains. Glycogen synthase kinase …
[HTML][HTML] Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth
Glycogen synthase kinase-3β (GSK-3β) is thought to mediate morphological responses to a
variety of extracellular signals. Surprisingly, we found no gross morphological deficits in …
variety of extracellular signals. Surprisingly, we found no gross morphological deficits in …
Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease
DE Hurtado, L Molina-Porcel, JC Carroll… - Journal of …, 2012 - Soc Neuroscience
Glycogen synthase kinase-3 (GSK-3) is linked to the pathogenesis of Alzheimer's disease
(AD), senile plaques (SPs), and neurofibrillary tangles (NFTs), but the specific contributions …
(AD), senile plaques (SPs), and neurofibrillary tangles (NFTs), but the specific contributions …
Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease
B DaRocha-Souto, M Coma, BG Perez-Nievas… - Neurobiology of …, 2012 - Elsevier
β-Amyloid (Aβ) plaques in Alzheimer (AD) brains are surrounded by severe dendritic and
axonal changes, including local spine loss, axonal swellings and distorted neurite …
axonal changes, including local spine loss, axonal swellings and distorted neurite …
[HTML][HTML] GSK-3β, a pivotal kinase in Alzheimer disease
M Llorens-Marítin, J Jurado, F Hernández… - Frontiers in molecular …, 2014 - frontiersin.org
Alzheimer disease (AD) is the most common form of age-related dementia. The etiology of
AD is considered to be multifactorial as only a negligible percentage of cases have a familial …
AD is considered to be multifactorial as only a negligible percentage of cases have a familial …
GSK-3 is essential in the pathogenesis of Alzheimer's disease
A Takashima - Journal of Alzheimer's disease, 2006 - content.iospress.com
Abstract Glycogen synthase kinase-3 (GSK-3) is a pivotal molecule in the development of
Alzheimer's disease (AD). GSK-3β is involved in the formation of paired helical filament …
Alzheimer's disease (AD). GSK-3β is involved in the formation of paired helical filament …
GSK-3β overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo
M Llorens-Martín, A Fuster-Matanzo, CM Teixeira… - Molecular …, 2013 - nature.com
Adult hippocampal neurogenesis (AHN) is crucial for the maintenance of hippocampal
function. Several neurodegenerative diseases such as Alzheimer's disease (AD) are …
function. Several neurodegenerative diseases such as Alzheimer's disease (AD) are …
Glycogen synthase kinase 3: a drug target for CNS therapies
RV Bhat, SL Budd Haeberlein… - Journal of …, 2004 - Wiley Online Library
Abstract Glycogen synthase kinase3 (GSK3) is emerging as a prominent drug target in the
CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's …
CNS. The most exciting of the possibilities of GSK3 lies within the treatment of Alzheimer's …